Equities

Dawnrays Pharmaceutical (Holdings) Ltd

Dawnrays Pharmaceutical (Holdings) Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.25
  • Today's Change0.01 / 0.81%
  • Shares traded68.00k
  • 1 Year change+14.68%
  • Beta0.4447
Data delayed at least 15 minutes, as of Nov 13 2024 06:36 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,067993786
Total Receivables, Net322403368
Total Inventory211242203
Prepaid expenses131515
Other current assets, total10791139
Total current assets1,7201,7441,511
Property, plant & equipment, net1,2251,3081,143
Goodwill, net241241241
Intangibles, net288295287
Long term investments232587
Note receivable - long term1065250
Other long term assets------
Total assets3,6233,6733,340
LIABILITIES
Accounts payable162224143
Accrued expenses108171157
Notes payable/short-term debt1206.4321
Current portion long-term debt/capital leases0.361.530.98
Other current liabilities, total278529375
Total current liabilities669932697
Total long term debt0.100.441.53
Total debt1218.4124
Deferred income tax949067
Minority interest4.587.9117
Other liabilities, total00.30176
Total liabilities7681,031959
SHAREHOLDERS EQUITY
Common stock808080
Additional paid-in capital4.242.912.52
Retained earnings (accumulated deficit)2,7622,5552,302
Treasury stock - common----0
Unrealized gain (loss)------
Other equity, total7.543.92(4.49)
Total equity2,8552,6422,381
Total liabilities & shareholders' equity3,6233,6733,340
Total common shares outstanding1,5001,4991,490
Treasury shares - common primary issue008.61
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.